Leerink Partners analyst Mike Kratky maintained a Buy rating on PROCEPT BioRobotics (PRCT – Research Report) on April 24 and set a price target of $91.00.
Mike Kratky’s rating is based on several positive indicators for PROCEPT BioRobotics. The company reported a notable 6% increase in first-quarter sales compared to consensus expectations, reaching $69.2 million. This performance was driven by strong U.S. sales and a significant 29% increase in international sales, demonstrating robust demand for their products across markets.
Furthermore, PROCEPT BioRobotics has raised its full-year 2025 sales guidance slightly above consensus, reflecting confidence in its future performance despite potential macroeconomic challenges and tariff impacts. The company has also maintained its gross margin guidance, indicating stable profitability expectations. These factors, combined with the company’s conservative approach to guidance and solid commercial execution, underpin Kratky’s Buy rating for the stock.
Kratky covers the Healthcare sector, focusing on stocks such as Dexcom, Edwards Lifesciences, and AxoGen. According to TipRanks, Kratky has an average return of 10.7% and a 37.50% success rate on recommended stocks.
In another report released on April 25, TD Cowen also reiterated a Buy rating on the stock with a $85.00 price target.